Mandarin, English, Cantonese and Japanese

Chinese, English and Japanese

Chinese Materia Medica, Pharmacology and toxicology of Chinese medicines; Cancer, liver and kidney diseases, metabolic diseases and autoimmune diseases; Chinese Medicine education

BMed, MMed, PhD

Professor Yibin Feng is currently the Professor (since September 2020), Acting Director (February 2020 – February 2021) and Director (February 2021 – April 2026) in School of Chinese Medicine, the University of Hong Kong. Professor Feng awarded Bachelor degree in Chinese Medicine from Yunnan University of Chinese medicine in China. He awarded his PhD degree in molecular medicine from Hokkaido University School of Medicine in Japan. He finished postdoctoral research in molecular pharmacology, Hokkaido University in 1999. In his early career , Professor Feng received various scholarships and research funds from Chinese Government, Japanese Government, Sumitomo social welfare consortium, FUJISAWA Pharmaceutical Limited Incorporation and TSUMURA KAMPO Pharmaceutical Limited Incorporation etc. His major research areas and research topics are standardization and quality control of Chinese medicines, pharmacological screening and safety evaluation of Chinese medicines; and pharmacological action and its mechanism of Chinese medicines, as well Chinese medicine education. In recent years, as a PhD supervisor and principal investigator, his research was supported by grants from the Hong Kong Government (RGC, ITF, HMRF,HKCMDF), donations (such as Pong Ding Yuen Endowment Fund for Education & Research in Chinese-Western Medicine, Wong’s Donation for molecular cancer research in Chinese medicines, the Gaia Family Trust, Hong Kong Government-Matching funding), Hong Kong Hospital Authority’s funding for Chinese Medicine, and various industry contract research funding etc.

Being an expert in the study of pharmacology and toxicology of Chinese medicines, as well as Chinese internal medicine, Professor Feng’s research focuses on clinical and experimental study for cancer and metabolic diseases by using recently developed techniques in bioinformatics, OMICS, pharmacology, immunology and evidence-based medicine. He is also committed to conduct substitute research for some endangered species and Chinese medicine education. As PI, he has engaged in local and international collaboration with scientists from Hong Kong, China, Chinese Mainland, Macau, China, Japan, UK, Canada, and USA. He has published more than 700 articles (over 200 SCI papers in which 30 of them IF>10-40, 50 of them IF >5-9 in reputable journals such as British Journal of Pharmacology IF9.743, Cancer Letters IF9.756, Hepatology International IF 9.029, International Journal of Biological Sciences IF 10.75, Theranostics IF11.600, Acta Pharmaceutica Sinica B IF14.9033, Science Advances IF14.136, Hepatology IF17.298, Signal Transduction and Targeted Therapy IF38.104, and Molecular Cancer IF41.444 etc.), proceedings, books and book chapters for exploring scientific and clinical evidence of Chinese medicines in prevention and treatment of cancer and metabolic diseases. Some of his books are national text books. He served as a lead guest editor for special issues of liver diseases and Cancer for academic journals in 2011, 2016, 2020, 2021, 2022 and 2023 such as Chinese Medicine, Molecules, Evidence-Based Complementary and Alternative medicine, Frontiers in Pharmacology etc. Most of his papers were published in top 1-10% journals in the categories of Integrative & Complementary Medicine, Pharmacy & Pharmacology, Cellular & Molecular biology, and Multidisciplinary Science, and some of which were highly cited. According to Google Scholar, total citations are 35781 and H index is 73 on 5 July 2026. He has been listed in various world ranking systems, e.g. one of “Highly Cited Researchers 2024” by Clarivate as the most influential in the world and as one of the world’s Top 1% scientists by Clarivate Analytics (Essential Science Indicators, ESI) in the past consecutive 10 years (2017-2026), he was also listed in Stanford University Ranking system as top2% since 2022, and ranked No.1 in Hong Kong and No.7 in the world in category of complementary and integrative medicine by AD scientific index since 2023. He was listed as one of the High Impact Researchers of Traditional Medicine in the world, jointly selected by Clarivate Analytics and the Haihe Laboratory of Modern Chinese Medicine in 2026.

He has taught subjects such as Chinese Materia Medica, Pharmacology of Chinese Medicines, Toxicology of Chinese Medicines, Chinese Internal Medicine and Pharmacology. Recently, he has been responsible for teaching Chinese Materia Medica, Pharmacology and toxicology of Chinese medicines, Oncology of Chinese Medicines and research methodology in Chinese medicine.

Cancer, diabetes, obesity, liver diseases and renal diseases etc.

Highly active in international communities of Integrative & Complementary Medicine, Pharmacy & Pharmacology, Cellular & Molecular biology, and Multidisciplinary Science, serving as editor or reviewer for the following international journals:

Associate Editor and Editorial Board Members (over10 journals): (1) Frontiers in Pharmacology, (2) Integrative Cancer Therapy, (3) Chinese Medicine, (4) BMC Complementary Medicine and Therapies, (5) Evidence-Based Complementary and Alternative Medicine (eCAM), (6) Chinese Journal of Integrative Medicine, (7)Phytomedicine,(8) Journal of Ovarian Research, etc. 4 Guest editor for Chinese Medicine, eCAM, Molecules, Frontiers in Pharmacology in 2010, 2016, 2021 and 2022, and 4 Guest Associate Editor for eCAM, 2016, Frontiers in Oncology and Frontiers in Pharmacology in 2020, 2021 and 2022.

Reviewers (over 70 journals):Chinese Journal of Integrative Medicine, Journal of integrative medicine, eCAM, BMC Complementary Medicine and Therapies, Journal of Enthnopharmacology, Phytomedicine, Chinese Medicine, American Journal of Chinese Medicine, Journal of Ginseng Research, Frontiers in Pharmacology, Liver international, Cancers, Oxidative Medicine and Cellular Longevity, BBA-Molecular Cell Research, Molecular Oncology, Expert Opinion on Therapeutic Targets, BBA-Molecular Cell Research, Free Radical Biology and Medicine, Pharmacological Research IF10.334, Gut Microbes IF 10.245, British Journal of Pharmacology IF9.473, Cancer Letters IF9.756, Phytomedicine IF 11.3, Journal of Experimental and Clinical Cancer Research IF 12.658, Acta Pharmaceutica Sinica B IF14.903, Clinical and Translational Medicine IF11.492, Theranostics IF11.556, Medicinal Research Reviews IF12.944, Theranostics IF11.556, Journal for ImmunoTherapy of Cancer IF13.751, Nature Metabolism IF13.511, Advanced Science IF16.806, Cellular and Molecular Gastroenterology and Hepatology(CMGH) IF9.225, Hepatology IF 17.425, Signal Transduction and Targeted Therapy IF38.104, and Molecular Cancer IF41.444 etc..

PUBLICATIONS (More than 700 among which over 250 SCI papers)

SELECTED PUBLICATIONS (*CORRESPONDING AUTHOR)

1. Chen G, Lai S, Lin G, Li T, Qi X, Zhang C, Chen G, Tang G, Wang N, Feng Y*. Non-coding RNAs: Modulators of Signaling Pathways and Prognostic Biomarkers in Digestive System Cancer. Molecular Cancer, 2026 Apr 1. doi: 10.1186/s12943-025-02549-7. Online ahead of print. (IF: 33.9/35.9, Q1, 4/319, BIOCHEMISTRY & MOLECULAR BIOLOGY).
2. Chen G, He Q, Xiao Q, Ai J, Qin Z, Zhong Z, Zou J, Chen B, Zhang C, Feng Y*. The role of Chinese medicines in targeting non-coding RNAs to overcome cancer drug resistance: Mechanisms and clinical translation challenges. Pharmacol Res. 2025 Dec;222:108049. doi: 10.1016/j.phrs.2025.108049. Epub 2025 Nov 24. (IF10.5/10.3, Q1, 13/352, PHARMACOLOGY & PHARMACY).
3. Chen G, Chen B, Wu Y, Nie H, Zhong Z, Yang S, Qin R, Kang W, Zhang C, Wang N, Feng Y*. Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development. Mol Cancer. 2025 Jul 14;24(1):194. (IF: 33.9/35.9, Q1, 4/319, BIOCHEMISTRY & MOLECULAR BIOLOGY).
4. Zhao J, Sun Y, Feng Y*, Rong J*. Brain specific RagA overexpression triggers depressive-like behaviors in mice via activating ADORA2A signaling pathway. Advanced Science, 2024, 2404188. 2024 Oct 7:e2404188. doi: 10.1002/advs.202404188. (IF14.3, Q1).
5. Wu J, Tang G, Cheng CS, Yeerken R, Chan YT, Fu Z, Zheng YC, Feng Y*, Wang N*. Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery. Molecular Cancer 2024 Oct 1;23(1):218. doi: 10.1186/s12943-024-02136-2. (IF27.7, Q1, 5yIF 31).
6. Zhang C, Sun TT, Lv Y, Li X, Ling Y, Wang N, Xia W, Fan X, Feng Y*. A Chinese herbal formula Kesuting Syrup against COVID-19: Leveraging multidimensional computations in network pharmacology-driven experimental and clinical trials. 2024 Feb;14(2):e1569. doi: 10.1002/ctm2.1569. (IF 10.07, Q1).
7. Kubi JA, Brah AS, Cheung KMC, Chen ACH, Lee YL, Lee KF, Qiao W, Feng Y, Yeung KWK. Low-molecular-weight estrogenic phytoprotein suppresses osteoporosis development through positive modulation of skeletal estrogen receptors. Bioactive Materials 42 (2024) 299–315. (IF 18, Q1).
8. Wu J, Chan YD, Lu Y, Wang N*, Feng Y*. The tumor microenvironment in the post-surgical liver: mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma. Medicinal Research Review 2023 Apr 27. doi: 10.1002/med.21967. Online ahead of print. (IF 12.388, Q1).
9. Chen G, Wang N, Yang R, Wu Y, Liu J, Huang Z, Zhang Z, Huang Y, Zhang C, Chan Y, Feng Y*. Efficacy and safety of herbal medicines intervention for cachexia associated with cancer: A systematic review and meta-analysis. Phytotherapy Research 2023 Oct 5. doi: 10.1002/ptr.7956. Online ahead of print. (IF 7.2, Q1).
10. Xiong RG, Li JH, Cheng J, Wu SX, Huang SY, Zhou DD, Saimaitti A, Shang A, Tang GY, Li HB, Gan RY, Feng Y*. New insights into the protection of diatary components on anxiety, depression, and other mental disorders caused by contaminants and food additives. Trends Food Sci Technol. 2003 Aug;138:44-56. (15.3, Q1).
11. Chan YD, Tan H, Lu Y, Zhang C, Cheng C, Wu J, Wang N*, Feng Y*. Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharmaceutica Sinica B 2023, Apr;13(4):1554-1567. doi: 10.1016/j.apsb.2023.01.020. Epub 2023 Feb 2. (IF 14.903/10.891, Q1).
12. Zhong Z, Vong CT, Chen F, Tan HY, Zhang C, Wang N, Cui L, Wang Y*, Feng Y*. The immunomodulatory potential of natural products from herbal medicine as immune checkpoints inhibitors: helping to fight against cancer via multiple-targets. Med Res Rev. 2022;1–34. (IF 12.944/ 12.197). Review.
13. Chan YT, Lu Y, Wu J, Zhang C, Tan HY, Bian ZX, Wang N*, Feng Y*. CRISPR- Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. Theranostics 2022; 12(7): 3329-3344. doi: 10.7150/thno.71144. Review. (IF 11.600/ 11.629, Q1).
14. Feng Z, Wu J, Lu Y, Chan YT, Zhang C, Wang D, Luo D, Huang Y, Feng Y*, Wang N*. Circulating tumor cells in the early detection of human cancers. Int J Biol Sci. 2022 May 1;18(8):3251-3265. (IF: 10.7500, Q1).
15. Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y*. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Front Immunol. 2022 Mar 8;13:857308. doi: 10.3389/fimmu.2022.857308. eCollection 2022. (IF 8.786/7.624, Q1).
16. Zhang C, Tam CW, Tang G, Chen Y, Tan HY, Wang N, Feng Y*.  Single-cell co-expression analysis using computational machine learning reveals oxidative, immunopathologic, and myocardial responses for multi-organ failure in COVID-19. Clinical and Translational Medicine 2022;12:e1049. DOI: 10.1002/ctm2.1049 (IF 8.554/8.601, Q1).
17. Lu Y, Chan YT, Tan HT, Zhang C, Guo W, Xu Y, Sharma R, Chen ZS, Zheng YC, Wang N*, Feng Y*. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p /ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research 2022, 41:3. (IF 12.658/ 9.976). Original.
18. Wang N, Zhang C, Xu Y, Tan HY, Chen H, Feng Y*. Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1α/VEGF activation in retina endothelial cells. International Journal of Biological Sciences 2021 Oct 20;17(15):4316-4326. doi: 10.7150/ijbs.62868. eCollection 2021.PMID: 34803500. (IF 10.750/6.479). Original.    
19. Tan HY, Wang N, Zhang C, Chan YT, Yuen MF, Feng Y*. LOXL4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. Hepatology 2021 May. 2021 Jun; 73 (6): 2326-2341. (IF 17.298/ 16.555, Q1). Original.
20. Wang N, Tan HY, Lu Y, Chan YT, Wang D, Guo W, Xu Y, Zhang C, Chen F, Tang G, Feng Y*. PIWIL1 Governs the Crosstalk of Cancer Cell Metabolism and Immunosuppressive Microenvironment in Hepatocellular Carcinoma. Signal Transduction and Target Therapy 2021 Feb; 6 (1): 86. (IF 38.103/ 21.178, Q1). Original. 
21. Xu Y, Wang N, Tan HY, Li S, Zhang C, Zhang Z, Feng Y *. Panax notoginseng Saponins Modulate the Gut Microbiota to Promote Thermogenesis and Beige Adipocyte Reconstruction via Leptin-Mediated AMPKα/STAT3 Signaling in Diet-Induced Obesity. Theranostics. 2020 Sep; 10 (24): 11302-11323. (IF 11.600/ 11.629, Q1). Original. 
22. Tan HY, Ho VWT, Chan YT, Zhang C, Wang N, Xia W, Feng Y*. Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula is therapeutic in non-small cell lung cancer acting via Rap1/cdc42 Signaling: a Transcriptomics/ Bio-informatics biological validation approach. Pharmacological Research 2019 Aug 26:104415. doi: 10.1016/j.phrs.2019.104415. (IF 10.334/7.377, Q1, 19/270 in Pharmacology and Pharmacy, Q1). Original.
23. Wang N, Tan HY, Li S, Wang D, Xu Y, Zhang C, Xia W, Che CM, Feng Y*. SBP2 Deficiency in Adipose Tissue Macrophages Drives Insulin Resistance in Obesity. Science Advances 2019 Aug; 5 (8): eaav0198. (IF 14.958/ 16.449, citation 10). Original.
24. Wang N, Tan H, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis. Theranostics. 2017 Jun; 7 (8): 2325-2338. (IF 11.600/ 11.629, Q1). Original.
25. Cheng CS, Tan HY, Wang N, Chen L, Meng Z, Chen Z*, Feng Y*. Functional Inhibition of Lactate Dehydrogenase Suppresses Pancreatic Adenocarcinoma Progression. Clinical and Translational Medicine 2021 Jun; 11 (6): e467. (IF 8.554/ 8.601, Q1). Original. 
26. Chen F, Zhong Z, Tan HY, Guo W, Zhang C, Cheng CS, Wang N, Ren J*, Feng Y*. Suppression of lncRNA MALAT1 by Betulinic Acid Inhibits Hepatocellular Carcinoma Progression by Targeting IAPs via miR-22-3p. Clinical and Translational Medicine 2020 Oct; 10 (6): e190. (IF 8.554/ 8.601, Q1). Original. 
27. Zhang C, Feng YG, Tam C, Wang N, Feng Y*. Transcriptional profiling and machine learning unveil a diagnostic concordant biosignature of Type I interferon-mediated host response across nasopharyngeal swab and pulmonary tissue for COVID-19. Frontiers in Immunology 2021 Nov 22;12:733171. doi: 10.3389/fimmu.2021.733171. eCollection 2021. (IF 8.786/7.624, Q1).
28. Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y*. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Frontiers in Immunology 2022 Mar 8;13:857308. doi: 10.3389/fimmu.2022.857308. eCollection 2022. (IF 8.786/7.624, Q1)
29. Wang N, Pan W, Zhu M, Zhanf M, Hao X, Liang G, Feng Y*. Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal of Pharmacology 2011;164(2b): 731-742. (IF9.473/7.956, Q1).
30. Zhang C, Wang N, Tan H, Guo W, Chen F, Zhong Z, ManK, TsaoS, LaoL, Feng Y*. Direct inhibition of TLR4/MyD88 pathway by geniposide suppresses HIF1α- independent VEGF expression and hepatocellular carcinoma angiogenesis. British Journal of Pharmacology 2020 Mar 6. doi: 10.1111/bph.15046. [Epub ahead of print]. (IF 9.473/7.956, Q1). Original.
31. Li S, Wang N, Tan HY, Chueng F, Zhang ZJ, Yuen MF, Feng Y*. Modulation of Gut Microbiota Mediates Berberine-Induced Expansion of Immuno-Suppressive Cells to against Alcoholic Liver Disease. Clinical and Translational Medicine 2020 Aug; 10 (4): e112. (IF 8.554/ 8.601,Q1). Original. 
32. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation mediates tumor associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death and Disease (2015) 6, e; doi:10.1038/cddis.2015.271 (Nature group, IF 9.685/8.713, Q1).
33. Wang N, Wang L, Zhang C, Tan HY, Zhang Y, Feng Y*. Berberine suppresses advanced glycation end products-associated diabetic retinopathy in hyperglycemic mice. Clinical and Translational Medicine 2021 Nov;11(11):e569. (IF 8.554/ 8.601, Q1). Original.
34. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y*. MiR-23a-Mediated Inhibition of Topoisomerase 1 Expression Potentiates Cell Response to Etoposide in Human Hepatocellular Carcinoma. Molecular Cancer 2013 Oct; 12 (1): 119. (IF 41.444/ 20.259, Q1). Original.
35. Tan HY, Wang N, Lam W, Guo W, Feng Y*, Cheng YC*. Targeting tumour microenvironment by tyrosine kinase inhibitor. Molecular Cancer 2018 Feb 19;17(1):43. doi: 10.1186/s12943-018-0800-6. (IF 41.444/20.260, Q1, Citation). Review.
36. Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y*. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharm Sin B. 2021 Sep;11(9):2749-2767. doi: 10.1016/j.apsb.2020.12.020. Epub 2021 Feb 2. Review (IF 14.903/10.891, Q1).
37. Lu Y, Chan YT, Tan HT, Zhang C, Guo W, Xu Y, Sharma R, Chen Z, Zheng Y, Wang N*, Feng Y*. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2022, 41:3. (IF 11.161/ 9.976,Q1).
38. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y*. Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. Hepatol Int. 2021 Apr;15(2):350-365. doi: 10.1007/s12072-021-10138-1. Epub 2021 Mar 3. (IF 9.029/5.9751, Q1)
39. Wang N, Wang L, Zhang C, Tan HY, Zhang Y, Feng Y*. Berberine suppresses advanced glycation end products-associated diabetic retinopathy in hyperglycemic mice. Clin Transl Med. 2021 Nov;11(11):e569. (IF 11.492/ 8.601).
40. Lu Y, Chan YT, Tan HY, Li S, Wang N*, Feng Y*. Epigenetic Regulation in Human Cancer: The Potential Role of Epi-Drug in Cancer Therapy. Mol Cancer. 2020 Apr; 19 (1): 79. (IF 41.444/20.260, Q1).
41. Qu Y, Dou B, Tan HY, Feng Y*, Wang N*, Wang D*. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Molecular Cancer 2019 Mar 30; 18(1):69. (IF 41.444/20.260, Q1).  
42. Ye XS, Feng Y*, Tong Y, Ng KM, Tsao SW, Lau George KK, Sze CW, Zhang YB, Tang J, Shen JG, Kobayashi S. Hepatoprotective effects of Coptidis Rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats. Journal of Ethnopharmacology 2009, 124:130–136.
43. Li S, Cheng CS, Zhang C, Tang GY, Tan HY, Chen HY, Wang N, Lai AY, Feng Y*. Edible and Herbal Plants for the Prevention and Management of COVID-19. Front Pharmacol. 2021 Apr 28;12:656103. doi: 10.3389/fphar.2021.656103. eCollection 2021. Review. (IF 5.988/ 6.006)
44. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. Journal of Ethnopharmacology 2011,138: 683-90. (IF 5.195/4.489, Q1).
45. Feng Y*, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, Tong Y, Kobayashi S. Hepatoprotective effects of berberine on carbon tetrachloride- induced acute liver hepatotoxicity in rats. Chinese Medicine 2010, 5:33 (1-6. (IF5.455/4.422).
46. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine 2009, 5 (1), 2. (IF 3.404, 5-year IF 4.044).
47. Feng Y, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y. Chinese medicines as a resource for liver fibrosis treatment. Chinese medicine 2009,4 (1), 1-11. (IF5.455/4.422).

SELECTED BOOKS AND CHAPTERS IN BOOKS (* CORRESPONDING AUTHOR)

1. Xu HX, Feng Y*, Wang XB, Editor in Chief. Toxicology of Chinese Medicines. Shanghai Science and Technology Publishing House. August 2023, 1th edition，pp325. ISBN 9787547862537). (in Chinese).
2. Xu HX, Feng Y*, Zhu GF, Editor-in-Chief. Anticancer Chinese Medicines: Origen, chemistry, pharmacology and clinical application. Shanghai: Science Publisher. 2018, ISBN 978-7-5478-4080-1/R 1657, pp884. (In Chinese).
3. Chen Chang-xun (Editor in Chief). Editorial board: Cao HY, Chen LY, Chen YF, Fang XY, Feng Y, Gu WL, Gu Y, Hua YQ, Huang LL, Nie Hong, Qu F, Shen YH, Solos L, Wang B, Wang J, Wang N, Wang XB, Wang YY, Xu HB, Yu S, Zhang JX. Pharmacology of Chinese Materia Medica. National “Thirteenth Five-Year_Plan” Inovative Textbooks for higher education in Chinese Medicine. China Press of Traditional Chinese Medicine. Beijing. Pp267 (in English).
4. Chen Dexing, Wen xiapin (Editor in Chief), Editorial board: Chen BZ, Chen DX, Du GL, Fan Y, Feng Y, Hu FL, Hua HM, Jia P, Ni C, Nian L, Ruan SB, Wang F, Wang JN, Wen XP, Xin ZP, Xu XD, Yu Y, Yun XL. National Textbook for Chinese Medicine Prescription. Qinghua University Press, 1th edition, 2013. Beijing, China. pp394 (in Chinese). 
5. Xie Mengzhou (Editor in Chief). Editorial board: Shang YQ, Yi W, Zhou J, Wu ZZ, Nie H, Shi LP, Tian SL, Feng Y, Sun ZM, Li HT, Zhang B, Lin Y, Jin H, Zhou Y, Zhao XW, Guo T, Liang XW, Xie XJ, Tai X, Sun GX. National Textbook for diet therapy. Zhong Guo Zhong Yi Yao Chu Ban She (China Chinese medicine and Chinese medicines publisher), 2nd edition, 2013. Beijing, China. pp387. (in Chinese)
6. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y*. Molecular and Cellular Mechanism Studies on Anticancer Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp332-362). ISBN 978-953-307-514-3. 2011, pp644. (in English).
7. Feng Y, Chen XM, Wang N and Shen JG*. Current Progress on Medicinal Plants and their Biological Properties in Contemporary China. Chapter in Recent Progress in Medicinal Plants Vol. 28: Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. (English).
8. Tong Y and Feng Y. Assessments in the Bachelor of Chinese Medicine (BChinMed) Programme. Chapter in The assessment of the University of Hong Kong. 2009, pp51-58. Published by Institute of Medical and Health Sciences Education, Li Ka Shing Faculty of Medicine, The University of Hong Kong. (English).